Natrelle® Style 133 Tissue Expanders 133MV-12Recalls & reported problems
Allergan, Inc. · NATRELLE 133MV-12, 300 cc · Class U · Implant
All models of Natrelle Breast Implants (1167) · Natrelle Style 133 Tissue Expanders (42)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.
- Adverse event reports
- 3
- Deaths reported
- 0
- Injuries reported
- 3
- Recalls naming it
- 1
Summary
The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 10888628004115), received between Oct 5, 2018 and Apr 28, 2022 — classified as 3 injuries.
1 FDA recall record name this device's identifier, 1 still open.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Recalls naming this device
- Jul 24, 2019Class IOpen, Classified
The action was initiated following notification by the U.S. FDA of their recently updated, global safety information concerning the higher incidence of anaplastic large cell lymphoma (BIA-ALCL) in patients who have textured breast implants.
Z-2455-2019 · Root cause: Unknown/Undetermined by firm · Recall details · FDA record ↗
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem2
- No Apparent Adverse Event1
Patient problems
- Unspecified Infection2
- Cellulitis1
Recent adverse event reports
The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.
InjuryApr 28, 2022Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
PATIENT REPRESENTATIVE REPORTED "IF PATIENT KNEW OF THE SIGNIFICANT POTENTIAL HEALTH RISKS OF ALLERGAN¿S NATRELLE STYLE 410 FX IMPLANTS, THEY WOULD NEVER HAVE HAD ALLERGAN¿S BIOCELL PRODUCT IMPLANTED IN THEIR BODY. AS A RESULT OF THE IMPLANTATION OF ALLERGAN¿S DEFECTIVE NATRELLE STYLE 410 FX IMPLANT, PATIENT HAS SUFFERED PHYSICAL COMPLAINTS AND SYMPTOMS, ALL OF WHICH ARE CAUSALLY CONNECTED TO ALLERGAN¿S NATRELLE STYLE 410 FX IMPLANT. PATIENT HAS EXPERIENCED PAIN UNDER THEIR ARMPITS, UNDER AND ACROSS CHEST, BACKPAIN, PAIN WHEN TAKING DEEP BREATHS. DIFFICULTY WITH SEXUAL ACTIVITY, NUMBNESS, STIFFNESS, PULLING, ACHING, SHOOTING PAIN INTO THE ARMPITS, SHOULDER PAIN ,NECK PAIN, TINGLING AND NUMBNESS IN ARMS, HANDS, FINGERS, LOSS OF STRENGTH IN ARMS AND HANDS, DENTAL ISSUES, MUSCULO SKELETAL COMPLAINTS, REDNESS, SWELLING, SHOULDER PAIN, STIFFNESS. FORMATION OF SCARS AROUND THE INCISION, NERVE, BACK AND NECK PAIN, DIVOTS, SORENESS, FEVER, INFECTION AND DISCOMFORT. PATIENT ALSO SUFFERED FROM AND PRESENTLY SUFFERS GREAT FEAR THAT ALLERGAN¿S RECALLED AND DEFECTIVE NATRELLE STYLE 410 FX IMPLANT WILL RESULT IN THEM EXPERIENCING BIA-ALCL AND/OR DEATH." THE DEVICE HAS BEEN EXPLANTED. THIS RECORD
Patient problems: Unspecified Infection
MAUDE report 14240424 ↗InjuryOct 7, 2021Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
PATIENT REPRESENTATIVE REPORTED "IF PATIENT KNEW OF THE SIGNIFICANT POTENTIAL HEALTH RISKS OF ALLERGAN¿S NATRELLE STYLE 410 FX IMPLANTS, THEY WOULD NEVER HAVE HAD ALLERGAN¿S BIOCELL PRODUCT IMPLANTED IN THEIR BODY. AS A RESULT OF THE IMPLANTATION OF ALLERGAN¿S DEFECTIVE NATRELLE STYLE 410 FX IMPLANT, PATIENT HAS SUFFERED PHYSICAL COMPLAINTS AND SYMPTOMS, ALL OF WHICH ARE CAUSALLY CONNECTED TO ALLERGAN¿S NATRELLE STYLE 410 FX IMPLANT. PATIENT HAS EXPERIENCED PAIN UNDER THEIR ARMPITS, UNDER AND ACROSS CHEST, BACKPAIN, PAIN WHEN TAKING DEEP BREATHS. DIFFICULTY WITH SEXUAL ACTIVITY, NUMBNESS, STIFFNESS, PULLING, ACHING, SHOOTING PAIN INTO THE ARMPITS, SHOULDER PAIN ,NECK PAIN, TINGLING AND NUMBNESS IN ARMS, HANDS, FINGERS, LOSS OF STRENGTH IN ARMS AND HANDS, DENTAL ISSUES, MUSCULO SKELETAL COMPLAINTS, REDNESS, SWELLING, SHOULDER PAIN, STIFFNESS. FORMATION OF SCARS AROUND THE INCISION, NERVE, BACK AND NECK PAIN, DIVOTS, SORENESS, FEVER, INFECTION AND DISCOMFORT. PATIENT ALSO SUFFERED FROM AND PRESENTLY SUFFERS GREAT FEAR THAT ALLERGAN¿S RECALLED AND DEFECTIVE NATRELLE STYLE 410 FX IMPLANT WILL RESULT IN THEM EXPERIENCING BIA-ALCL AND/OR DEATH." THE DEVICE HAS BEEN EXPLANTED. THIS RECORD
Patient problems: Unspecified Infection
MAUDE report 12590683 ↗InjuryOct 5, 2018No Apparent Adverse Event; No Apparent Adverse Event
HEALTH PROFESSIONAL REPORTED PATIENT EXPERIENCED "CELLULITIS". THIS IS THE LEFT SIDE RECORD. DEVICE REMAINS IMPLANTED.
Patient problems: Cellulitis
MAUDE report 7939224 ↗
Other Expander, Skin, Inflatable devices
- B.BRAUN 7B3050B. Braun Medical Inc. · EXPANDER, SKIN, INFLATABLE1 recall40 reports
- MENTOR CPX 4 Breast Tissue Expander with Suture Tabs 3549314Mentor Texas L.P. · EXPANDER, SKIN, INFLATABLE1 recall22 reports
- MENTOR CPX4 PLUS, Smooth, Medium Height SCPX146MHMentor Texas L.P. · Expander, skin, inflatable1 recall18 reports
- Natrelle® Style 133 Tissue Expanders with Suture Tabs 133MX-13-TAllergan, Inc. · Expander, Skin, Inflatable1 recall16 reports
- MENTOR ARTOURA PLUS, Smooth, Ultra High Profile SDC135UHMentor Texas L.P. · Expander, skin, inflatable1 recall14 reports
- MENTOR ARTOURA PLUS, Smooth, High Profile SDC150HMentor Texas L.P. · Expander, skin, inflatable1 recall14 reports
- MENTOR ARTOURA PLUS, Smooth, Ultra High Profile SDC120UHMentor Texas L.P. · Expander, skin, inflatable1 recall14 reports
- Natrelle® Style 133 Tissue Expanders with Suture Tabs 133MV-14-TAllergan, Inc. · Expander, Skin, Inflatable1 recall13 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026 · each recall links to the FDA recall notice
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page